Ropidoxuridine in Treating Patients With Advanced Gastrointestinal Cancer Undergoing Radiation Therapy
NCT02381561 · Status: ACTIVE_NOT_RECRUITING · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 19
Last updated 2026-04-13
Summary
This phase I trial studies the side effects and best dose of ropidoxuridine in treating patients with gastrointestinal cancer that has spread to other places in the body and usually cannot be cured or controlled with treatment undergoing radiation therapy. Ropidoxuridine may help radiation therapy work better by making tumor cells more sensitive to the radiation therapy.
Conditions
- Advanced Bile Duct Carcinoma
- Stage II Esophageal Cancer AJCC v7
- Stage II Pancreatic Cancer AJCC v6 and v7
- Stage IIA Esophageal Cancer AJCC v7
- Stage IIA Pancreatic Cancer AJCC v6 and v7
- Stage IIB Esophageal Cancer AJCC v7
- Stage IIB Pancreatic Cancer AJCC v6 and v7
- Stage III Colon Cancer AJCC v7
- Stage III Esophageal Cancer AJCC v7
- Stage III Gastric Cancer AJCC v7
- Stage III Liver Cancer
- Stage III Pancreatic Cancer AJCC v6 and v7
- Stage III Rectal Cancer AJCC v7
- Stage III Small Intestinal Cancer AJCC v7
- Stage IIIA Colon Cancer AJCC v7
- Stage IIIA Esophageal Cancer AJCC v7
- Stage IIIA Gastric Cancer AJCC v7
- Stage IIIA Rectal Cancer AJCC v7
- Stage IIIA Small Intestinal Cancer AJCC v7
- Stage IIIB Colon Cancer AJCC v7
- Stage IIIB Esophageal Cancer AJCC v7
- Stage IIIB Gastric Cancer AJCC v7
- Stage IIIB Rectal Cancer AJCC v7
- Stage IIIB Small Intestinal Cancer AJCC v7
- Stage IIIC Colon Cancer AJCC v7
- Stage IIIC Esophageal Cancer AJCC v7
- Stage IIIC Gastric Cancer AJCC v7
- Stage IIIC Rectal Cancer AJCC v7
- Stage IV Colon Cancer AJCC v7
- Stage IV Esophageal Cancer AJCC v7
- Stage IV Gastric Cancer AJCC v7
- Stage IV Liver Cancer
- Stage IV Pancreatic Cancer AJCC v6 and v7
- Stage IV Rectal Cancer AJCC v7
- Stage IV Small Intestinal Cancer AJCC v7
- Stage IVA Colon Cancer AJCC v7
- Stage IVA Liver Cancer
- Stage IVA Rectal Cancer AJCC v7
- Stage IVB Colon Cancer AJCC v7
- Stage IVB Liver Cancer
- Stage IVB Rectal Cancer AJCC v7
Interventions
- RADIATION
-
Intensity-Modulated Radiation Therapy
Undergo IMRT
- OTHER
-
Laboratory Biomarker Analysis
Correlative studies
- OTHER
-
Pharmacological Study
Correlative studies
- DRUG
-
Ropidoxuridine
Given PO
Sponsors & Collaborators
-
National Cancer Institute (NCI)
lead NIH
Principal Investigators
-
Timothy J Kinsella · Rhode Island Hospital
Study Design
- Allocation
- NA
- Purpose
- TREATMENT
- Masking
- NONE
- Model
- SINGLE_GROUP
Eligibility
- Min Age
- 18 Years
- Sex
- ALL
- Healthy Volunteers
- No
Timeline & Regulatory
- Start
- 2016-02-01
- Primary Completion
- 2018-11-08
- Completion
- 2027-03-14
Countries
- United States
Study Locations
More Related Trials
-
GI-101/GI-101A as a Single Agent or in Combination With Pembrolizumab or Lenvatinib in Advanced Solid Tumors
NCT04977453 ·Status: RECRUITING ·Phase: PHASE1/PHASE2
-
Efficacy and Safety of Adjunctive Use of Rifaximin In Preventing Radiotherapy-induced Diarrhea in Cancer Patients
NCT06783153 ·Status: NOT_YET_RECRUITING ·Phase: PHASE1/PHASE2
-
A Phase I/II Study of Regorafenib Plus Avelumab in Solid Tumors
NCT03475953 ·Status: RECRUITING ·Phase: PHASE1/PHASE2
-
Study of Crenolanib With Ramucirumab and Paclitaxel for Advanced Esophagogastric Adenocarcinoma
NCT03193918 ·Status: COMPLETED ·Phase: PHASE1
-
A Phase 2 Randomized, Open-Label Study of RRx-001 vs Regorafenib in Subjects With Metastatic Colorectal Cancer
NCT02096354 ·Status: COMPLETED ·Phase: PHASE2
-
S1613, Trastuzumab and Pertuzumab or Cetuximab and Irinotecan Hydrochloride in Treating Patients With Locally Advanced or Metastatic HER2/Neu Amplified Colorectal Cancer That Cannot Be Removed by Surgery
NCT03365882 ·Status: COMPLETED ·Phase: PHASE2
-
A Study of RGX-202-01 (Ompenaclid) as Combination Therapy in RAS Mutant Advanced Colorectal Cancer
NCT03597581 ·Status: COMPLETED ·Phase: PHASE1
-
Phase 3 Study of DCC-2618 vs Placebo in Advanced GIST Patients Who Have Been Treated With Prior Anticancer Therapies
NCT03353753 ·Status: COMPLETED ·Phase: PHASE3
-
Study to Assess the Safety and Efficacy of Intravenous Injection of the Imaging Agent 111In-IPN01087 in Patients With Locally Advanced or Metastatic Pancreatic or Colorectal Cancer.
NCT04632199 ·Status: WITHDRAWN ·Phase: PHASE1
-
Safety and Efficacy of Anlotinib in Combination With Irinotecan in Patients With Pretreated Advanced Colorectal Cancer
NCT03545711 ·Status: UNKNOWN ·Phase: PHASE1/PHASE2
-
Injection of SHR-A1811 Versus Physician Choiced Treatment in Patients With Advanced Colorectal Cancer Who Had Failed to Respond to Oxaliplatin, 5-fu, and Irinotecan
NCT06199973 ·Status: ACTIVE_NOT_RECRUITING ·Phase: PHASE3
-
Anti-PD-1 +/- RT for MSI-H Solid Tumors
NCT04001101 ·Status: WITHDRAWN ·Phase: PHASE2
-
Capecitabine, Oxaliplatin, Selenomethionine, and Radiation Therapy in Treating Patients Undergoing Surgery For Newly Diagnosed Stage II or III Rectal Adenocarcinoma
NCT00625183 ·Status: TERMINATED ·Phase: PHASE2
-
Radiation Therapy Plus Irinotecan in Treating Patients With Colon Cancer
NCT00003344 ·Status: COMPLETED ·Phase: PHASE1/PHASE2
-
S0713: Oxaliplatin, Capecitabine, Cetuximab, and RT Followed By Surgery in Pts W/Stage II or III Rectal Cancer
NCT00686166 ·Status: COMPLETED ·Phase: PHASE2
-
Regorafenib in Subjects With Metastatic Colorectal Cancer (CRC) Who Have Progressed After Standard Therapy
NCT01538680 ·Status: NO_LONGER_AVAILABLE
-
Capecitabine and 131I-huA33 in Patients With Metastatic Colorectal Cancer
NCT00291486 ·Status: COMPLETED ·Phase: PHASE1
-
Veliparib, Pembrolizumab, and Combination Chemotherapy in Treating Patient With Locally Advanced Rectal Cancer
NCT02921256 ·Status: COMPLETED ·Phase: PHASE2
-
Pembrolizumab and Autologous Dendritic Cells for the Treatment of Refractory Colorectal Cancer (CRC)
NCT05518032 ·Status: WITHDRAWN ·Phase: PHASE2
-
ZD 1839 in Treating Patients With Locally Advanced or Metastatic Colorectal Cancer
NCT00030524 ·Status: COMPLETED ·Phase: PHASE2
-
Phase I/II Study of SGI-110 With Irinotecan Versus Regorafenib or TAS-102 in Metastatic Colorectal Cancer
NCT01896856 ·Status: COMPLETED ·Phase: PHASE1/PHASE2
-
SB-715992 in Treating Patients With Advanced or Metastatic Colorectal Cancer
NCT00103311 ·Status: COMPLETED ·Phase: PHASE2
-
Lower or Standard Dose Regorafenib in Treating Patients With Refractory Metastatic Colorectal Cancer
NCT02368886 ·Status: COMPLETED ·Phase: PHASE2
-
Safety Study of Radio-labeled huA33 Antibody in Colorectal Cancer
NCT00199862 ·Status: COMPLETED ·Phase: NA
-
A Study Evaluating Regorafenib Following Completion of Standard Chemotherapy for Patients With Colon Cancer
NCT02664077 ·Status: TERMINATED ·Phase: PHASE3